CTRI/2023/07/055382已完成不适用
An open label randomized single dose two treatment two way crossover oral bioavailability study of investigational product in healthy adult human participants under fasting conditions.
YourZooki holdings Ltd1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2023年7月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Cmax AUC0-t AUC0-infinity.
研究概览
简要总结
Vitamin C is a water-soluble vitamin that is commonly used in food. It is utilized as an additive, because of its reducing and antioxidant properties. The usage of ascorbic acid in food is associated with a variety of biological activities such as the protection of oxidizable molecules, the retardation of enzymatic browning, oxygen scavenging, the prevention of nitrosamine production. The bioavailability and shelf life of bioactive components have both been improved by using encapsulation technology. Liposomes are vesicles that are simple models of highly complex cell membranes, consisting of lipid bilayers surrounding an aqueous core. Due to their unique biocompatibility and biodegradability, liposomes have attracted significant interest in the delivery and protection of both hydrophilic and hydrophobic compounds, such as vitamins. So liposomal encapsulated vitamin C helps to overcome the degradation of vitamin C due to high reactivity. It also improves the absorption into intestine by the controlled release of vitaminC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Normal healthy adult male and female Human participants of age between 21-65 years with a Body Mass Index (BMI) range between 18.50 kg/m2 to 24.99 kg/m
- •2.Plasma Ascorbic acid at screening <75μmol/
- •3.Subject agrees avoid vitamin C containing medications and dietary supplements from screening until last visit.
- •4.Subject agrees to avoid high activity physical exercise 72.00 hours prior to last visit 5.Subjects who have no evidence of underlying disease during screening and check- in and whose screening is performed within 29 days of check in.
- •6.Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator to be of no clinical significance.
- •7.Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
- •8.Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray and clinical laboratory assessments.
- •9.Non- smokers or ex-smokers.
- •Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months.
- •10.Willing to consume ova-lacto vegetarian diet.
- •11.Willing to comply to all requirements of this study protocol as well as instructed by the study personnel 12.Female subjects within normal limits or clinically non-significant laboratory evaluation results for FSH and LH.
- •13.Generally healthy as documented by gynecological examination and breast examination (for female subjects during Period-I check-in only).
- •14.Female subjects of childbearing potential; a.Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or b.Surgically sterile (bilateral tubal ligation).
排除标准
- •1.Evidence of allergy or known hypersensitivity to Vitamin C or other related drugs or other related drugs.
- •2.Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus, renal or liver impairment and pre-existing gallbladder disease.
- •3.Any major illness in the last three months or any significant ongoing chronic medical illness.
- •4.Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •5.History of alcohol addiction or abuse.
- •6.Malabsorption syndrome that affects vitamin c metabolism.
- •7.Heart failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with >100/min ventricular rate.
- •8.Gastrointestinal bleeding in past three months.
- •9.Uncontrolled diabetes mellitus.
- •10.Active psychiatric disorder, intention for suicidal, disorders with Unconsciousness.
- •11.Psychopathic disorder, lack of cooperation.
- •12.Chronic obstructive lung disease or active smoking (more than 2 cigarettes in the past 6 months) 13.Taking more than 100 mg vitamin C daily within 2 weeks to screening.
- •14.Consumption of caffeine and /or Xanthine containing products (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), tobacco containing products for at least 24.00 hours prior to check-in and throughout the entire study 15.Consumption of grapefruit and its juice and poppy containing foods for at least 72.00 hours prior to check-in and throughout the study.
- •16.Subjects who taken any prescription medications, over the counter medicinal products, herbal medications within 14 days prior to study check in and throughout the study.
- •17.History of dehydration from diarrhea, vomiting or any other reason within a period of 24.00 hours prior to study check-in of each period.
- •18.An unusual or abnormal diet within 48.00 hours prior to study check-in of each period, for whatever reason e.g. because of fasting due to religious reasons.
- •19.Subject who had participated in any other study within the 90 days of check-in.
- •20.History of difficulty in swallowing.
- •21.Positive results for drugs of abuse (Marijuana-THC, amphetamine-AMP, barbiturates-BAR, cocaine-COC, benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period.
结局指标
主要结局
Cmax AUC0-t AUC0-infinity.
时间窗: pre-dose blood sample 00.00 hours 05 ml will be collected within 60 minutes prior to dosing. Post dose blood samples 05 ml will be collected at 00.50, 01.00, 02.00, 06.00,12.00 ,24.00 & 48 hours.
次要结局
- tmax, Kel, t½.(pre-dose blood sample 00.00 hours 05 ml will be collected within 60 minutes prior to dosing. Post dose blood samples 05 ml will be collected at 00.50, 01.00, 02.00, 06.00,12.00 ,24.00 & 48 hours.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
"Novo C Plus" Vitamin C Containing Dietary Supplement Bioavailability in Healthy SubjectsVitamin C DeficiencyNCT02606773Semmelweis University32
尚未招募
不适用
Vitamin C's Antioxidant Effects and COPD PrognosisCOPD (Chronic Obstructive Pulmonary Disease)NCT06664957Ningbo No. 1 Hospital650
撤回
不适用
Bioavailability of Orally Ingested Vitamin CHealthyNCT05183880University of Exeter
招募中
2 期
Effect of High Dose Intravenous Vitamin C in Severe PneumoniaPneumoniaNCT05842382Clinical Research Centre, Malaysia484
招募中
2 期
High Dose Vitamin C Combined With Metformin in the Treatment of Malignant TumorsHepatocellular CancerColorectal CancerPancreatic CancerGastric CancerNCT04033107Zhongnan Hospital30